Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Study on the Value of C1q in the Diagnosis of Esophageal Cancer

Version 1 : Received: 5 September 2021 / Approved: 7 September 2021 / Online: 7 September 2021 (10:03:44 CEST)

How to cite: Cai, X.; Li, H.; Chen, J.; Tang, D.; Zhang, P. Study on the Value of C1q in the Diagnosis of Esophageal Cancer. Preprints 2021, 2021090116. https://doi.org/10.20944/preprints202109.0116.v1 Cai, X.; Li, H.; Chen, J.; Tang, D.; Zhang, P. Study on the Value of C1q in the Diagnosis of Esophageal Cancer. Preprints 2021, 2021090116. https://doi.org/10.20944/preprints202109.0116.v1

Abstract

Background: Esophageal cancer was hardly diagnosed in early stage, and more potential biomarkers should be found. Methods: 252 patients and normal controls which recruited in Renmin Hospital of Wuhan University, were divided into esophageal carcinoma group (105 cases), disease control group (75 cases) and the control group of healthy people (72 cases). Moreover, TISIDB and GEPIA databases were used to investigate the different expression of EC and normal tissues, and explore the roles of C1q in tumor-immune system interactions in EC. Results: The concentration of serum C1q in EC group is 196.8(180~219.4) mg/L, which is higher than the level of DC [178.10(153.70~200.85) mg/L]and HC [183.00(167.75~201.00) mg/L] (P<0.05). A higher expression level of C1q was observed in Ⅲ and Ⅳ grades [214(192~237.3) mg/ml] than grades Ⅰ and Ⅱ [180.95(172.03~193.85) mg/L] (P<0.05). C1q was positively correlated with eosinophils, active CD8 T cells, myeloid derived suppressor cells, natural killer cells, monocytes and macrophages (r = 0.373; r = 0.659; r = 0.846; r = 0.760; r = 0.499; r = 0.757; P<0.05). Conclusion: The concentrations of C1q increased in EC and related to the severity of EC, which had potential value of diagnosis of EC. There were correlations in C1q and tumor-infiltrating lymphocytes.

Keywords

C1q; Biomarker; Esophageal cancer; Diagnosis; Tumor

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.